An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4-ALK fusion gene

被引:28
|
作者
Toyokawa, Gouji [1 ]
Takenoyama, Mitsuhiro [1 ]
Taguchi, Kenichi [2 ]
Toyozawa, Ryo [1 ]
Inamasu, Eiko [1 ]
Kojo, Miyako [1 ]
Shiraishi, Yoshimasa [1 ]
Morodomi, Yosuke [1 ]
Takenaka, Tomoyoshi [1 ]
Hirai, Fumihiko [1 ]
Yamaguchi, Masafumi [1 ]
Seto, Takashi [1 ]
Shimokawa, Mototsugu [3 ]
Ichinose, Yukito [1 ]
机构
[1] Kyushu Natl Canc Ctr, Dept Thorac Oncol, Minami Ku, Fukuoka 8111395, Japan
[2] Kyushu Natl Canc Ctr, Inst Clin Res, Canc Pathol Lab, Fukuoka 8111395, Japan
[3] Kyushu Natl Canc Ctr, Inst Clin Res, Fukuoka 8111395, Japan
关键词
Small-cell lung cancer; Oncogenic driver mutation; EML4-ALK; MUTATIONS;
D O I
10.1016/j.lungcan.2013.05.022
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Anaplastic lymphoma kinase (ALK) fuses echinoderm microtubule-associated protein-like 4 (EML4) to acquire a transforming activity in lung adenocarcinomas. However, the presence of an EML4-ALK fusion gene in other lung cancer histologies is an extremely rare phenomenon. A 43-year-old female was referred to our department due to dyspnea on effort and left back pain. Computed tomography (CT) showed a large mass in the upper lobe of the left lung and a massive left pleural effusion, while a CT-guided needle biopsy confirmed a diagnosis of small-cell lung cancer (SCLC). Surprisingly, the tumor was genetically considered to harbor the EML4-ALK fusion gene (variant 2). Although the patient underwent two regimens of cytotoxic chemotherapy for SCLC, she died approximately seven months after the administration of first-line chemotherapy. Our analysis of 30 consecutive patients with SCLC for EML4-ALK revealed that two patients, including the current patient and a patient we previously reported, harbored the EML4-ALK fusion gene. (c) 2013 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:487 / 490
页数:4
相关论文
共 50 条
  • [41] Detection of the EML4-ALK fusion gene in non-small cell lung cancer: our FISH service to date
    Durajczyk, Clare
    Massie, D.
    Stevenson, D.
    Kerr, K.
    Smith, L.
    JOURNAL OF MEDICAL GENETICS, 2012, 49 : S53 - S53
  • [42] An effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer
    Kobayashi, Makoto
    Sakakibara, Tomohiro
    Inoue, Akira
    Fukuhara, Tatsuro
    Sasano, Hironobu
    Ichinose, Masakazu
    Nukiwa, Toshihiro
    RESPIRATORY INVESTIGATION, 2014, 52 (01) : 49 - 56
  • [43] A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK
    Anai, Satoshi
    Takeshita, Masafumi
    Ando, Nobuhisa
    Ikematsu, Yuuki
    Mishima, Shohei
    Ishida, Koichi
    Inoue, Kouji
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : E126 - +
  • [44] Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation
    Kuo, Yao-Wen
    Wu, Shang-Gin
    Ho, Chao-Chi
    Shih, Jin-Yuan
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : 2039 - 2040
  • [45] SEQUENCE COMPLEXITY OF EML4-ALK FUSION VARIANTS IDENTIFIED IN NON-SMALL CELL LUNG CANCER
    Zhang, Xu-Chao
    Wu, Yi-Long
    Tian, Hong-Xia
    Yang, Jin-Ji
    Yang, Xue-Ning
    Zhou, Qing
    Su, Jian
    Chen, Zhi-Hong
    An, She-Juan
    Zhi, Xie
    Guo, Wei-Bang
    Chen, Shi-Liang
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1009 - S1010
  • [46] Clinical Outcomes and ALK Resistance Mutations in ALK plus Non-Small Cell Lung Cancer According to EML4-ALK Variant
    Lin, J.
    Zhu, V.
    Yoda, S.
    Yeap, B.
    Jessop, N.
    Schrock, A.
    Dagogo-Jack, I.
    Gowen, K.
    Stephens, P. J.
    Ross, J.
    Ali, S.
    Miller, V.
    Gainor, J.
    Hata, A.
    Iafrate, A.
    Ou, S.
    Shaw, A.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1828 - S1828
  • [47] Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion
    Aguado, Cristina
    Gil, Maria-de-los-Llanos
    Yeste, Zaira
    Gimenez-Capitan, Ana
    Teixido, Cristina
    Karachaliou, Niki
    Viteri, Santiago
    Rosell, Rafael
    Molina-Vila, Miguel A.
    ONCOTARGETS AND THERAPY, 2018, 11 : 1117 - 1120
  • [48] The biology and treatment of EML4-ALK non-small cell lung cancer
    Sasaki, Takaaki
    Rodig, Scott J.
    Chirieac, Lucian R.
    Janne, Pasi A.
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (10) : 1773 - 1780
  • [49] Analysis of EML4-ALK fusion transcripts in plasma and platelets to monitor response to crizotinib in EML4-ALK positive non-small cell lung cancer patients (NSCLC)
    Aguado, Cristina
    Teixido, Cristina
    Gimenez-Capitan, Ana
    Gil, Maria de los Llanos
    Rodriguez, Sonia
    Viteri, Santiago
    Karachaliou, Niki
    Aldeguer, Erika
    Peg, Vicente
    Alonso, Lidia
    Molina-Vila, Miguel Angel
    Rosell, Rafael
    CANCER RESEARCH, 2017, 77
  • [50] Clinical effect of crizotinib on lung cancer patients with EML4-ALK fusion gene mutation
    Wang, Zhiyong
    Wang, Wei
    Kong, Xiaodong
    Li, Guangxu
    Yang, Weiwei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (09): : 11632 - 11638